Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …

Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Context Androgen-deprivation therapy (ADT) is a key component of treatment for aggressive
and advanced prostate cancer, but it has also been associated with adverse effects on bone …

During the past decade preclinical studies have defined many of the mechanisms used by
tumours to hijack the skeleton and promote bone metastasis. This has led to the …

There are three distinct areas of cancer management that make bone health in cancer
patients of increasing clinical importance. First, bone metastases are common in many solid …

Background Current approaches to diagnosing testosterone deficiency do not consider the
physiological consequences of various testosterone levels or whether deficiencies of …

Background Sipuleucel-T, an autologous active cellular immunotherapy, has shown
evidence of efficacy in reducing the risk of death among men with metastatic castration …

As one of the most common metastatic sites of malignancies, bone has a unique
microenvironment that allows metastatic tumor cells to grow and flourish. The fenestrated …

Abstract In 2009, the American Cancer Society (ACS) Prostate Cancer Advisory Committee
began the process of a complete update of recommendations for early prostate cancer …

Bisphosphonates are primary agents in the current pharmacological arsenal against
osteoclast-mediated bone loss due to osteoporosis, Paget disease of bone, malignancies …